A hi-tech prostate cancer drug that offers hope to men who have run out of treatment options became available in the UK today.
Enzalutamide is licensed for patients with advanced prostate cancer who are no longer responding to hormone treatments or chemotherapy.
What to expect from the new drug:
- The new pill will cost around £2,500 a month.
- It can extend the lives of patients no longer being treated by almost five months.
- Seven out of 10 of the men in the Phase III Affirm trial taking enzalutamide were still alive after one year.
- It has a relative lack of side effects.
- The drug known as Xtandi, blocks molecular signals that allow the male hormone testosterone to fuel prostate cancer.
- It targets three different steps of the signalling pathway.
More top news
Officers were given the touching letter at Brixton Station while they were on a reassurance patrol after yesterday's attack
The 52-year-old had previous convictions for violence but was not on the anti-terror watchlist.
In a statement Charlton Athletic said: Keith was a true hero who will be greatly missed by all the Charlton family and everyone at the club.